Oral Administration of Myelin Induces Antigen‐specific TGF‐β1 Secreting T Cells in Patients with Multiple Sclerosisa
- 17 December 1997
- journal article
- clinical trial
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 835 (1) , 120-131
- https://doi.org/10.1111/j.1749-6632.1997.tb48623.x
Abstract
Oral administration of antigen is a long-recognized method of inducing systemic immune tolerance. In animals with experimental autoimmune disease, a major mechanism of oral tolerance involves the induction of regulatory T cells that mediate active suppression by secreting the cytokine TGF-beta 1. Multiple sclerosis (MS) is a presumed T cell-mediated Th1 type autoimmune disease. In this paper we investigated, in patients with MS, whether oral myelin treatment (myelin containing both MBP and PLP) induced antigen-specific MBP- or PLP-reactive T cells that were either Th2-like (secreted IL-4 or TGF-beta 1), or alternatively whether Th1 type sensitization occurred as measured by IFN-gamma secretion. Specifically, 4,860 short-term T cell lines were generated to either MBP, PLP or TT from 34 relapsing-remitting patients with MS; 17 were orally treated with bovine myelin daily for a minimum of two years as compared to 17 non-treated patients. We found a marked increase in the relative frequencies of both MBP- and PLP-specific TGF-beta 1 secreting T cell lines in the myelin-treated MS patients as compared to non-treated MS patients (MBP, p < 0.001; PLP, p < 0.003). In contrast, no changes in the frequency of MBP- or PLP-specific IFN-gamma or TT-specific TGF-beta 1 secreting T cells were observed. These results suggest that the oral administration of antigens generates antigen-specific TGF-beta 1 secreting T cells of presumed mucosal origin that may represent a distinct cytokine-secreting lineage of T cells (Th3). Since, in animal models, antigen-specific TGF-beta 1 secreting cells localize to the target organ and then suppress inflammation in the local microenvironment, oral tolerization with self-antigens may provide a therapeutic approach for the treatment of cell-mediated autoimmune disease which does not depend upon knowledge of the antigen specificity of the original T cell clone triggering the autoimmune cascade.Keywords
This publication has 30 references indexed in Scilit:
- The expanding universe of T-cell subsets: Th1, Th2 and morePublished by Elsevier ,1999
- Three‐year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a Phase III Pivotal TrialAnnals of the New York Academy of Sciences, 1996
- Published by American Association for the Advancement of Science (AAAS) ,1994
- T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous systemEuropean Journal of Immunology, 1993
- Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple SclerosisScience, 1993
- Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.The Journal of Experimental Medicine, 1992
- Antigen-driven bystander suppression after oral administration of antigens.The Journal of Experimental Medicine, 1991
- Inflammatory and immunomodulatory roles of TGF-βImmunology Today, 1989
- The regulation of immune responses to dietary protein antigensImmunology Today, 1987
- Multiple SclerosisNew England Journal of Medicine, 1982